Contact


Mailing Address

Donate

Your tax deductible gift in any amount helps support our efforts to advocate for more research, better treatments, and ultimately, a cure for IH.

Donate
 

Arise Clinical Trial

Arise Clinical Trial

CLINICAL TRIAL ENROLLING PATIENTS WITH IDIOPATHIC HYPERSOMNIA AND NARCOLEPSY TYPE 2

Arise Clinical StudyBalance Therapeutics is evaluating an investigational new drug BTD-001, to treat excessive daytime sleepiness in individuals diagnosed with idiopathic hypersomnia (IH) or narcolepsy type 2 (Na-2). A Phase 2 clinical trial is currently enrolling Na-2 subjects at 26 investigational centers in the United States. Individuals currently diagnosed as “IH” who may have previously been diagnosed as narcolepsy may also qualify. For more information regarding the study and participating site locations, and if you are interested in participating in this trial, please visit the website www.arisestudies.com.

Background:

Recent research published by a team from Emory University in Atlanta, Georgia has demonstrated that the excessive daytime sleepiness in many individuals diagnosed with idiopathic hypersomnia (IH) and narcolepsy type 2 (narcolepsy without cataplexy; Na-2) is driven by accumulation of a naturally occurring substance, yet to be identified, that increases the function of the sleep promoting neurotransmitter γ (gamma)-amino-butyric acid (i.e., GABA) in the brain. 

The investigational drug BTD-001 is known to suppress GABA activity. BTD-001 is therefore targeted more directly at emerging mechanisms thought to cause the excessive sleepiness of many patients diagnosed with IH and Na-2. It is also unique from current FDA approved therapeutic approaches for alleviating the excessive daytime sleepiness in individuals diagnosed with IH and Na-2.

To learn more information about the clinical trial and see if you might qualify, please visit the website arisestudies.com.

 

arise

 

Save



Get “Somnusnooze”, our monthly e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive an email from info@hypersomniafoundation.org (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. We recommend that you add info@hypersomniafoundation.org to your contacts and/or safe email list (whitelist) to ensure you receive all future newsletters. Thank you for your interest in the Hypersomnia Foundation!